Hepatitis B: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• PD-1 4
• PD-L1 2
• TP53 0
• STAT3 0
• STING 0
• CD19 0
• TNF 0
• AMPK 0
• JAK 0
• mTOR 0
• CD20 0
• EGFR 0
• ERK 0
• GPC3 0
• HIF-1 0
• IL-1 0
• IL-6 0
• PI3K 0
• PPAR 0
• TFEB 0
• ABL1 0
• AKT 0
• BCL-2 0
• CTLA-4 0
• G6PD 0
• HMGB1 0
• HSP90 0
• IL-17 0
• MYC 0
• NRF2 0
• PARP 0
• VEGF 0
• ALK 0
• AQP4 0
• ARID1A 0
• CCR5 0
• CD33 0
• CD38 0
• CD40 0
• CTNNB1 0
• FAK 0
• FGFR 0
• HDAC 0
• IL-23 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MAPK 0
• METTL3 0
• MMP-9 0
• NLRP3 0
• NOTCH1 0
• PKM2 0
• PNPLA3 0
• PRMT5 0
• PSMA 0
• PTEN 0
• SGLT2 0
• TERT 0
• TIM-3 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding Immune Aging in Chronic Hepatitis B (DECAGE)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €209,483· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Implementation of an Integrated Digital Health System for Infectious Diseases in Maternal and Child Health In East Africa (LINDA-FAMILIA)

  University College Cork - National University of Ireland, Cork· Cork, Ireland· EU contribution €4,998,563· until Jul 2029· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Innovative Point of Care for combined screening of Infectious diseases: application to Prevention of Mother to Child Transmission (MAGFA)

  Magia Diagnostics· Echirolles, France· EU contribution €5,078,816· until Dec 2027· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Acquired adaptive immune cell dysfunction and restoration in chronic hepatitis B (EUCLIDEAN)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €2,500,000· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-RIA

  Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D (D-SOLVE)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €6,754,010· until Sept 2027· 5 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 7 running projects, newest first. Listed amounts together: €32.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 12
• Organoids 3
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 23
• Gene Expression Profiling 26
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 10
• Mass Spectrometry 2
• Flow Cytometry 3
• Immunohistochemistry 4
• Liquid Biopsy 2
• Xenograft Model Antitumor Assays 2
• Magnetic Resonance Imaging 22
• Machine Learning 38
• Deep Learning 6
• Cohort Studies 63
• Genome-Wide Association Study 12

• Aptamer-CRISPR/Cas as a tool in point-of-care testing of infectious diseases.

  Talanta, Oct 2026

• Emerging techniques of CRISPR/Cas system in antiviral therapy and diagnostics: Applications, limitations, and translational perspectives.

  J Virol Methods, Aug 2026

• Chromatin Accessibility-Guided Targeting Identifies Structurally Constrained Regions in HBV cccDNA and Suppresses Viral Replication.

  Int J Mol Sci, Aug 2026

• A light-activated one-pot ERA/CRISPR-Cas12a assay for cost-effective dual-mode detection of HBV DNA.

  Talanta, Jul 2026

• Development of RPA and nested-RPA based CRISPR/Cas13a diagnostic platform for the identification of HBV DNA and HCV RNA in Indian patient cohort.

  Diagn Microbiol Infect Dis, Jun 2026

• CRISPR-Cas13a/Cas12a Assisted Dual Portable and Visualized HDV and HBV Detection.

  J Med Virol, Jun 2026

• A Rapid Assay for Hepatitis C Virus RNA Detection Using Reverse-Transcription Loop-Mediated Isothermal Amplification-Coupled CRISPR-Cas12b-Based Strategy.

  J Infect Dis, May 2026

• Targeting human oncogenic viruses with CRISPR/Cas: New therapeutic opportunities and challenges.

  Biomed Pharmacother, Apr 2026

• Nanoparticle-based biosensor integrated with CRISPR/Cas12b platform for sensitive and visual identification of hepatitis B virus pregenomic RNA in chronic hepatitis B patients.

  BMC Microbiol, Mar 2026

• Homogeneous electrochemical sensor for sensitive detection of HBV DNA based on magnetic separation and CRISPR/Cas12a protein trans-cleavage.

  Talanta, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.